Research programme: therapeutics - BridgeBio Pharma/University of Pittsburgh
Latest Information Update: 28 Jul 2021
At a glance
- Originator BridgeBio Pharma; University of Pittsburgh
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Unspecified